ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SUMM Summit Therapeutics Plc

20.50
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Summit Therapeutics Plc LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 20.50 18.00 23.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Summit Therapeutics Share Discussion Threads

Showing 40326 to 40347 of 41850 messages
Chat Pages: Latest  1614  1613  1612  1611  1610  1609  1608  1607  1606  1605  1604  1603  Older
DateSubjectAuthorDiscuss
05/9/2018
11:31
Hi waterloo01 - mention in article below
chrisatrdg
05/9/2018
11:10
RNS
Regulatory Story
Go to market news section View chart Print
Summit Therapeutics plc - SUMM


Summit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea Released 12:00 05-Sep-2018

Summit Therapeutics plc
(‘Summit’; or the ’Company’;)

Summit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea

SMT-571 Designed to Exploit Novel N. gonorrhoeae Target Identified by Discuva Platform
Details Presented at ESCMID/ASM Conference
New Corporate Website Launched Highlighting Summit’s Antibiotic Innovation
Oxford, UK, and Cambridge, MA, US, 5 September 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that it has nominated SMT-571 as its lead clinical candidate from its first gonorrhoea series. New mechanism antibiotics are important in the fight against gonorrhoea, as the pathogen is becoming increasingly resistant to the only recommended treatment option. Just last week, the US Centers for Disease Control and Prevention (‘CDC’) reported preliminary data that gonorrhoea cases in the US increased by 67% between 2013 and 2017 and with resistant cases on the rise, the CDC stated that additional treatment options for gonorrhoea are urgently needed.

In in vitro studies, SMT-571 killed N. gonorrhoeae through a novel target involved in cell division, which was identified using Summit’s Discuva Platform. SMT-571 has demonstrated potent in vitro activity against clinical isolates of N. gonorrhoeae, including multi-drug resistant strains. With the nomination, Summit is progressing SMT-571 into investigational new drug (‘IND’)-enabling studies. The Company plans to initiate a Phase 1 clinical trial of SMT-571 in the second half of 2019. The development SMT-571 is supported by a CARB-X award worth up to $4.5 million and granted in July of this year, which covers its development through the end of the Phase 1 clinical trial subject to certain milestones being met.

“We believe our new science and new way of thinking together enable our goal to develop the right drug for the right pathogen and create opportunities for success,” said Dr David Roblin, President of R&D of Summit. “SMT-571 is being developed specifically for gonorrhoea, meaning that it is designed to have both a targeted spectrum of activity and be tailored to meet the needs of patients with gonorrhoea.”

SMT-571 is designed to be an oral treatment for gonorrhoea and to have activity across the three sites of gonorrhoea infection: genital, rectal and pharyngeal.

Details of SMT-571 are being presented at the ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance taking place 4-7 September in Lisbon, Portugal. A copy of the poster is available in the Publications section of the Company’s website, www.summitplc.com.

In addition, Summit launched a new corporate website today at www.summitplc.com to highlight the Company’s innovation in antibiotics, including its gonorrhoea programme.

About Gonorrhoea
It is estimated by the World Health Organization (‘WHO’) that there are approximately 78 million new cases of gonorrhoea globally per year. Neisseria gonorrhoeae has consistently developed resistance to each class of antibiotics recommended for treatment and there is now only one treatment recommended by the CDC, a combination of two antibiotics. There are currently no other recommended antibiotics that can be effectively deployed to target the disease. The WHO ranks as “High” the priority of R&D investment into the search for antibiotics which are effective against Neisseria gonorrhoeae and in August 2018, the CDC stated that in light of increased problems with resistance, additional treatment options were urgently required.

About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR).

The development of SMT-571 is supported by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by an award from Wellcome Trust. The contents of this announcement are solely the responsibility of the authors and do not necessarily represent the official views of the HHS Office of the Assistant Secretary for Preparedness and Response, Wellcome Trust, CARB-X or its funders.

Contacts

Summit
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455

Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson

N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate Finance
Tom Salvesen, Corporate Broking

Panmure Gordon (Joint Broker) Tel: +44 (0)20 7886 2500
Freddy Crossley, Corporate Finance
James Stearns, Corporate Broking

MSL Group (US) Tel: +1 781 684 6557
Jon Siegal summit@mslgroup.com

Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Jessica Hodgson / summit@consilium-comms.com
Lindsey Neville
Summit Forward-looking Statements

Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the potential benefits of the CARB-X award, including whether the option segments will be exercised, the clinical and preclinical development of the Company’s product candidates, the therapeutic potential of the Company’s product candidates, the potential commercialisation of the Company’s product candidates, the sufficiency of the Company’s cash resources, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that the Company makes with the Securities and Exchange Commission, including the Company’s Annual Report on Form 20-F for the fiscal year ended 31 January 2018. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

-END-


CLOSE

chrisatrdg
05/9/2018
10:20
Chris, remind me about Roche. What was their involvement in antibiotics?
waterloo01
05/9/2018
09:32
MAJOR SHAREHOLDERS
Summit had been notified of the following holdings of more than 3% or more of the issued share capital of the Company

Name % Holding
Lansdowne Partners Limited 25.8%
Robert Keith 6.1%
Hargreave Hale Limited 4.5%

Information reviewed on 3 September 2018

chrisatrdg
05/9/2018
09:20
Said it before never normally invest in biotech firms as they are Russian roulette and you just have the one shot but summit seem to have a gun with a few bullets in it sorry I mean products so if one fails you still got a couple that may come to market good luck tomorrow and all long-term shareholders and course newbies
football
05/9/2018
09:16
Nice! Hopefully not long before an update
kirk 6
05/9/2018
08:53
Just logged in to Summit again & the updates are now there this morning roll on Thursday.

Edit: I think I might have been a bit late just seen new logo above well done.

Edit: The Roch deal as now shown goes back to 2014 under the 'Old Ownership'.

Edit: I have just logged in for this Thursdays event & note that we will be 'watching it' - something new & maybe something big to happen? (Time for a coffee I think).

chrisatrdg
05/9/2018
08:12
A nice new logo at the top of the page here as well
football
05/9/2018
08:09
So is it a complete new website ready for tomorrow's announcements if any?


Seems all the pages date/went live from approximately 6 o'clock last night

football
05/9/2018
08:01
Not noticed that before. Is this the 1st mention of Roche?
waterloo01
05/9/2018
07:57
“And undisclosed targets in collaboration with Roche”
freedosh
05/9/2018
07:25
Interesting post football.

I saw those pages last night and they were new (including a new Summit logo). Today the pages are not available or have reverted back to the originals.

This says to me that SUMM are about to announce their new strategy and new branding / website.

Possible tie in with tomorrow's presentation? either way, news to come here soon. imo.

someuwin
04/9/2018
22:36
new update to pages on website
football
04/9/2018
09:27
Should be interesting,especially if they reveal any specific new Targets they are going after as well as the C Difficile and Gonorrhea.
algernon2
04/9/2018
08:50
CEO presentation and live webcast of SUMM's plans going forward, this Thursday. Should be interesting!

"Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn Edwards, Chief Executive Officer, will present on the Company's plans to advance its new mechanism antibiotic pipeline at the Rodman & Renshaw 20(th) Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, 6 September 2018 at 11:15am EDT in New York City.

A live webcast of the presentation will be available in the Investors section of the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation."

someuwin
03/9/2018
11:07
Total voting rights RNS



Edit: This will be a prelim to the 6 months results expect soon.

Edit: This was issued at 11.00 this morning so I guess not a formal RNS.

chrisatrdg
31/8/2018
10:53
Bitcoin nowhere to be seen 😂
the canadian mounted
31/8/2018
07:23
Up 15% at the end on decent volume. Results in the next few weeks.
waterloo01
30/8/2018
20:23
Edit up over 10% on Nasdaq
kirk 6
30/8/2018
20:18
Not bad up over 8%. Roll on tomorrow
kirk 6
30/8/2018
17:49
Its been up here before in recent weeks. I am not getting carried away ..... yet !
luminoso
30/8/2018
17:00
This dog can fly!
the canadian mounted
Chat Pages: Latest  1614  1613  1612  1611  1610  1609  1608  1607  1606  1605  1604  1603  Older

Your Recent History

Delayed Upgrade Clock